Cannabis Suisse Corp.

As of November 30, 2025, Cannabis Suisse Corp. carries a market capitalization of 515,970.85, placing it among publicly traded companies globally. Its enterprise value stands at 2.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of November 30, 2025, Cannabis Suisse Corp. has 70.68M shares outstanding.

As of November 30, 2025, Cannabis Suisse Corp. trades at a trailing price-to-earnings ratio of 5.09. The price-to-sales ratio is 34.40, and the price-to-book ratio stands at -0.29.

These figures are as of November 30, 2025. The EV/Sales ratio of 176.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Cannabis Suisse Corp. trades at an EV/FCF ratio of 660.37, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.65M versus a market cap of 515,970.85, with the gap driven by net debt and cash on the balance sheet.

As of November 30, 2025, Cannabis Suisse Corp. maintains a current ratio of 0.19, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -120.36, indicating conservative leverage, while an interest coverage ratio of -4.40 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended November 30, 2025. Return on invested capital (ROIC) is negative at -49.47, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 15.08, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 28.47, useful for judging operating efficiency across full business cycles.

As of the close on October 21, 2026, Cannabis Suisse Corp.'s stock has declined approximately 57.22% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Over the twelve months ended November 30, 2025, Cannabis Suisse Corp. generated 15,000.00 in revenue and converted that into 101,336.00 in net income, yielding earnings per share of 0.00. EBITDA reached -283,910.00, while operating income came in at -288,154.00.

These figures are as of November 30, 2025. Total book value stands at -1.77M, with working capital of -316,580.00 providing operational flexibility.

Cannabis Suisse Corp. produced -60,472.00 in operating cash flow over the twelve months ended November 30, 2025.

Over the twelve months ended November 30, 2025, Cannabis Suisse Corp. posted a gross margin of 1.92, reflecting its pricing power and cost economics. The operating margin of -1,921.03 and net profit margin of 675.57 provide insight into operational efficiency.

These figures cover the twelve months ended November 30, 2025. Free cash flow yield is negative at -4.94: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.73, meaning Cannabis Suisse Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cannabis Suisse Corp.'s most recent stock split took place on February 28, 2019 with a 1:20 split ratio.

As of November 30, 2025, Cannabis Suisse Corp. has an Altman Z-Score of -10.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.